LBRM TG6 (ATCC® CRL-1778)

Organism: Mus musculus, mouse  /  Cell Type:: T lymphocyte; radiation induce  /  Disease: lymphoma

Permits and Restrictions

View Restrictions

Organism Mus musculus, mouse
Cell Type T lymphocyte; radiation induce
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease lymphoma
Strain B10.BR
Applications
The LBRM TG6 line was derived from the LBRM 33 T cell lymphoma (see ATCC TIB-155).
The cells produce IL-2 in response to IL-1 and PHA.
These cells can be used to measure IL-1 activity in a very rapid and sensitive assay.
Tested and found negative for ectromelia virus (mousepox).
Derivation
The LBRM TG6 line was derived from the LBRM 33 T cell lymphoma (see ATCC TIB-155).
Receptor Expression
interleukin 1 (IL-1)
Genes Expressed
interleukin 2; IL-2; interleukin-2
Cellular Products
interleukin 2; IL-2; interleukin-2
Comments
The LBRM TG6 line was derived from the LBRM 33 T cell lymphoma (see ATCC TIB-155).
The cells produce IL-2 in response to IL-1 and PHA.
These cells can be used to measure IL-1 activity in a very rapid and sensitive assay.
Tested and found negative for ectromelia virus (mousepox).
Complete Growth Medium Iscove's modified Dulbecco's medium with 0.02 mM 2-mercaptoethanol, 90%; fetal bovine serum, 10%
Subculturing
Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Name of Depositor JW Larrick
References

Larrick JW, et al. An improved assay for the detection of interleukin 1. J. Immunol. Methods 79: 39-45, 1985. PubMed: 3873500

Basic Documentation
Restrictions

the depositor has provided these cells for research purposes only and with the following restrictions: (1) no distribution should be made to third parties, (2) any proposed commercial use must be negotiated with the Cetus Corporation, 1400 Fifty-Third St., Emeryville, California 94608, (3) all papers reporting any use of these or derived clones should make direct reference to the original publication (J. Immunol. Methods 79:39-45, 1985)

References

Larrick JW, et al. An improved assay for the detection of interleukin 1. J. Immunol. Methods 79: 39-45, 1985. PubMed: 3873500